ADAM10 and triple-A syndrome: Recently, miR-103a (Jiao et al., 2017) was reported as an “anti-aneurysmal” miRNA that suppresses inflammation within the aortic wall, limiting AAA formation and progression by downregulating the protease ADAM Metallopeptidase Domain 10 (ADAM10).